{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-21-032831","form_type":"8-K","ticker":"RTGN","cik":"0001836295","company_name":"RetinalGenix Technologies Inc.","filed_at":"2021-12-30T23:59:59+00:00","discovered_at":"2026-05-14T18:04:14.575398+00:00","generated_at":"2026-06-27T21:45:42.206803+00:00","sec_items":["1.01","3.02","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"RetinalGenix exchanges 28M shares for pre-funded warrant; outstanding shares drop to 14.2M","bullets":["Exchanged 28,014,540 shares held by Sanovas Ophth for a pre-funded warrant to purchase same number of shares at $0.0001 per share.","Outstanding shares reduced from ~42.2M to 14,166,114 after cancellation of exchanged shares.","Transaction with related party: CEO Jerry Katzman is sole manager of Sanovas Ophth.","Warrant is immediately exercisable and terminates when exercised in full; no new cash received.","Issued under Section 3(a)(9) exemption; no additional consideration was paid."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-21-032831","json":"https://secwatch.observer/filing/0001493152-21-032831.json","markdown":"https://secwatch.observer/filing/0001493152-21-032831.md","text":"https://secwatch.observer/filing/0001493152-21-032831.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1836295/000149315221032831/0001493152-21-032831-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1836295/000149315221032831/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-27T21:45:42.206803+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}